专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明公开

KR1020090019848A 알쯔하이머 병의 진행에 대한 생체마커 无效
标题翻译：生物标志物对阿尔茨海默病的进展
公开(公告)号：KR1020090019848A
公开(公告)日：2009-02-25
申请号：KR1020087030933
申请日：2007-06-18
申请人： 노파르티스 아게
发明人： 헤,윤셍 , 고메즈-만실라,발타자르 , 메이어,조안 , 로벨리,지오르지오 , 쿤,라이네르알. , 빌베,그라엠
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , C12Q2600/156 , C12Q2600/158 , C12Q2600/172 , C12Q2600/118
摘要： The genetic polymorphism LRRK2 (leucine-rich repeat kinase 2)-T1602S is significantly associated with conversion from mild cognitive impairment (MCI) to Alzheimer's disease (AD), with the patients with TT genotype being at greater risk to progress to Alzheimer's disease. The LRRK2-T2352 also showed a trend for conversion to Alzheimer's disease, with the patients with CC genotype tending to progress to Alzheimer's disease. Similar to the APOE-E4 allele, in the presence of a BuChE-K variant, LRRK2-T1602S and LRRK2-T2352 showed a greater association with the rate of conversion from mild cognitive impairment to Alzheimer's disease. In another study with placebo-treated Alzheimer's disease patients, LRRK2-T1602S and LRRK2-T2352 showed a same trend of association. The Alzheimer's disease patients with TT genotype of LRRK2-T1602S or CC genotype of LRRK2-T2352 tended to decline faster on cognitive performance over 6 months, especially in the presence of a BuChE-K variant. The association between the two common LRRK2 polymorphisms and Alzheimer's disease progression shows that LRRK2 may play a role in Alzheimer's disease pathogenesis, especially disease progression, and that polymorphisms of LRRK2 can be used as biomrkers of this progression.
摘要翻译：遗传多态性LRRK2（富含亮氨酸的重复激酶2）-T1602S与轻度认知障碍（MCI）转变为阿尔茨海默病（AD）显着相关，TT基因型患者进入阿尔茨海默氏病的风险更大。 LRRK2-T2352也显示出转化为阿尔茨海默病的趋势，CC基因型患者往往进展为阿尔茨海默氏病。与APOE-E4等位基因相似，在BuChE-K变体存在下，LRRK2-T1602S和LRRK2-T2352显示与从轻度认知障碍转变为阿尔茨海默氏病的速率更大的关联。在安慰剂治疗的阿尔茨海默病患者的另一项研究中，LRRK2-T1602S和LRRK2-T2352显示出相同的关联趋势。具有LRRK2-T1602S的TT基因型或LRRK2-T2352的CC基因型的阿尔茨海默氏病患者在6个月以上的认知功能上往往更快下降，特别是在存在BuChE-K变体的情况下。两种常见的LRRK2多态性与阿尔茨海默病进展的关系表明，LRRK2可能在阿尔茨海默氏病发病机制中发挥重要作用，特别是疾病进展，LRRK2的多态性可作为这一进展的生物学家。

2. 发明公开

KR1020110055682A 간독성과 연관된 ＨＬＡ 대립형질을 보유하지 않은 환자에서 ＣＯＸ-2 의존성 장애의 치료를 위한 ＣＯＸ-2 억제제의 용도 无效
标题翻译：使用COX-2抑制剂治疗患有COX-2依赖性疾病的患者，不携带与肝细胞毒性相关的HLA ALLELE
公开(公告)号：KR1020110055682A
公开(公告)日：2011-05-25
申请号：KR1020117006420
申请日：2009-08-20
申请人： 노파르티스 아게
发明人： 레위츠키,스티븐 , 메이어,조안 , 파울딩,찰스 , 싱어,조나단,벤자민
IPC分类号： C12Q1/68 , G01N33/15 , A61K31/196
CPC分类号： C12Q1/6883 , C12Q2600/106 , C12Q2600/142 , C12Q2600/156 , Y10T436/143333 , A61K31/196 , G01N33/15
摘要： This disclosure relates to a method of determining the presence of at least one HLA allele, preferably selected from the group consisting of DQA1*0102, DRB1*1501, DQB1*0602 and DRB5*0101 to assess whether a patient is at risk for developing hepatotoxicity upon administration of the COX-2 inhibitor lumiracoxib. Also disclosed is the use of a kit for carrying out this method. The disclosure also relates to a method of treating cyclooxygenase-2 dependent disorders with lumiracoxib in a subject that is not a carrier of one or more HLA alleles, preferably selected from the group consisting of DQA1*0102, DRB1*1501, DQB1*0602 and DRB5*0101.

3. 发明公开

KR1020130100906A 취약 Ｘ 증후군 （ＦＸＳ） 치료에 유용한 예측용 마커 无效
标题翻译：预防性标志物用于治疗易感性X综合征（FXS）
公开(公告)号：KR1020130100906A
公开(公告)日：2013-09-12
申请号：KR1020127031312
申请日：2011-04-28
申请人： 노파르티스 아게
发明人： 고메즈-만시야,발타자르 , 히,윤성 , 존스,도날드 , 메이어,조안 , 파울딩,찰스
IPC分类号： C12Q1/68 , C12N15/11 , G01N33/53
CPC分类号： C12Q1/6883 , C12Q2600/106 , C12Q2600/154 , C12Q2600/158 , G01N33/5308
摘要： The invention is directed to the use of biomarkers to determine responsiveness of an individual with Fragile X Syndrome (FXS) to treatment with an mGluR5 antagonist.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式